Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) tinted gains of +2.18% (+0.51 points) to US$23.86. The volume of 0.26 Million shares climbed down over an trading activity of 238.24 Million shares. EPS ratio determined by looking at last 12 month figures is -0.27. Over the same time span, the stock marked US$23.4 as its best level and the lowest price reached was US$14.4. The corporation has a market cap of US$1.1 Billion.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s earnings per share has been growing at a -15.9 percent rate over the past 5 year when average revenue increase was noted as 3.3 percent. The return on equity ratio or ROE stands at -4.6 percent while most common profitability ratio return on investment (ROI) was -1.2 percent. The company’s institutional ownership is monitored at 46.3 percent. The company’s net profit margin has achieved the current level of -5.6 percent and possesses 35 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 2. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
SPS Commerce, Inc. (NASDAQ:SPSC) is worth US$1.65 Billion and has recently risen 2.76% to US$94.66. The latest exchange of 0.28 Million shares is below its average trading activity of 172.29 Million shares. The day began at US$92.86 but the price moved to US$92.28 at one point during the trading and finally capitulating to a session high of US$95.34. The stock tapped a 52-week high of US$100.68 while the mean 12-month price target for the shares is US$95.44.
Currently, the stock carries a price to earnings ratio of 102.56, a price to book ratio of 5.25, and a price to sales ratio of 6.83. For the past 5 years, the company’s revenue has grown 23.4%, while the company’s earnings per share has grown 32.5%. With an institutional ownership near 97.7%, it carries an earnings per share ratio of 0.92.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 5 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 1 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.91.